Cargando…

Prognostic and predictive values of tumour budding in stage IV colorectal cancer

BACKGROUND: Tumour budding is an important prognostic feature in early‐stage colorectal cancer, but its prognostic significance in metastatic disease has not been fully investigated. METHODS: Patients with stage IV disease who had primary colorectal tumour resection without previous chemotherapy or...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, K., Shinto, E., Yamadera, M., Shiraishi, T., Kajiwara, Y., Okamoto, K., Mochizuki, S., Hase, K., Kishi, Y., Ueno, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397347/
https://www.ncbi.nlm.nih.gov/pubmed/32472647
http://dx.doi.org/10.1002/bjs5.50300
_version_ 1783565760268861440
author Nagata, K.
Shinto, E.
Yamadera, M.
Shiraishi, T.
Kajiwara, Y.
Okamoto, K.
Mochizuki, S.
Hase, K.
Kishi, Y.
Ueno, H.
author_facet Nagata, K.
Shinto, E.
Yamadera, M.
Shiraishi, T.
Kajiwara, Y.
Okamoto, K.
Mochizuki, S.
Hase, K.
Kishi, Y.
Ueno, H.
author_sort Nagata, K.
collection PubMed
description BACKGROUND: Tumour budding is an important prognostic feature in early‐stage colorectal cancer, but its prognostic significance in metastatic disease has not been fully investigated. METHODS: Patients with stage IV disease who had primary colorectal tumour resection without previous chemotherapy or radiotherapy from January 2000 to December 2018 were reviewed retrospectively. Budding was evaluated at the primary site and graded according to the criteria of the International Tumor Budding Consensus Conference (ITBCC) (BD1, low; BD2, intermediate; BD3, high). Patients were categorized by metastatic (M1a, M1b) and resectional (R0/R1, R2/unresected) status. Subgroups were compared for overall (OS) and recurrence‐free (RFS) survival in R0/R1 subgroups; R2/unresected patients were evaluated for the rate of tumour progression, based on change in tumour size from baseline. RESULTS: Of 371 patients observed during the study, 362 were analysed. Patients with BD3 had a lower 5‐year OS rate than those with BD1 + BD2 (18·4 versus 40·5 per cent; P < 0·001). Survival analyses according to metastatic and resection status also showed that BD3 was associated with shorter OS than BD1 + BD2. In multivariable analysis, BD3 (hazard ratio (HR) 1·51, 95 per cent c.i. 1·11 to 2·10; P = 0·009), T4 status (HR 1·39) and R2/unresected status (HR 3·50) were associated with decreased OS. In the R0/R1 subgroup, the 2‐year RFS rate was similar for BD3 and BD1 + BD2 according to metastatic status. There was no significant difference between BD3 and BD1 + BD2 for change in tumour size in the R2/unresected subgroup (P = 0·094). Of 141 patients with initially unresectable metastases who had chemotherapy, 35 achieved conversion from unresectable to resectable status. The conversion rate was significantly higher for BD1 + BD2 than for BD3 (36 versus 18 per cent; P = 0·016). CONCLUSION: Stage IV colorectal cancer with high‐grade tumour budding according to ITBCC criteria correlates with poor prognosis.
format Online
Article
Text
id pubmed-7397347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-73973472020-08-06 Prognostic and predictive values of tumour budding in stage IV colorectal cancer Nagata, K. Shinto, E. Yamadera, M. Shiraishi, T. Kajiwara, Y. Okamoto, K. Mochizuki, S. Hase, K. Kishi, Y. Ueno, H. BJS Open Original Articles BACKGROUND: Tumour budding is an important prognostic feature in early‐stage colorectal cancer, but its prognostic significance in metastatic disease has not been fully investigated. METHODS: Patients with stage IV disease who had primary colorectal tumour resection without previous chemotherapy or radiotherapy from January 2000 to December 2018 were reviewed retrospectively. Budding was evaluated at the primary site and graded according to the criteria of the International Tumor Budding Consensus Conference (ITBCC) (BD1, low; BD2, intermediate; BD3, high). Patients were categorized by metastatic (M1a, M1b) and resectional (R0/R1, R2/unresected) status. Subgroups were compared for overall (OS) and recurrence‐free (RFS) survival in R0/R1 subgroups; R2/unresected patients were evaluated for the rate of tumour progression, based on change in tumour size from baseline. RESULTS: Of 371 patients observed during the study, 362 were analysed. Patients with BD3 had a lower 5‐year OS rate than those with BD1 + BD2 (18·4 versus 40·5 per cent; P < 0·001). Survival analyses according to metastatic and resection status also showed that BD3 was associated with shorter OS than BD1 + BD2. In multivariable analysis, BD3 (hazard ratio (HR) 1·51, 95 per cent c.i. 1·11 to 2·10; P = 0·009), T4 status (HR 1·39) and R2/unresected status (HR 3·50) were associated with decreased OS. In the R0/R1 subgroup, the 2‐year RFS rate was similar for BD3 and BD1 + BD2 according to metastatic status. There was no significant difference between BD3 and BD1 + BD2 for change in tumour size in the R2/unresected subgroup (P = 0·094). Of 141 patients with initially unresectable metastases who had chemotherapy, 35 achieved conversion from unresectable to resectable status. The conversion rate was significantly higher for BD1 + BD2 than for BD3 (36 versus 18 per cent; P = 0·016). CONCLUSION: Stage IV colorectal cancer with high‐grade tumour budding according to ITBCC criteria correlates with poor prognosis. John Wiley & Sons, Ltd 2020-05-29 /pmc/articles/PMC7397347/ /pubmed/32472647 http://dx.doi.org/10.1002/bjs5.50300 Text en © 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of British Journal of Surgery Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Nagata, K.
Shinto, E.
Yamadera, M.
Shiraishi, T.
Kajiwara, Y.
Okamoto, K.
Mochizuki, S.
Hase, K.
Kishi, Y.
Ueno, H.
Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title_full Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title_fullStr Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title_full_unstemmed Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title_short Prognostic and predictive values of tumour budding in stage IV colorectal cancer
title_sort prognostic and predictive values of tumour budding in stage iv colorectal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397347/
https://www.ncbi.nlm.nih.gov/pubmed/32472647
http://dx.doi.org/10.1002/bjs5.50300
work_keys_str_mv AT nagatak prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT shintoe prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT yamaderam prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT shiraishit prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT kajiwaray prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT okamotok prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT mochizukis prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT hasek prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT kishiy prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer
AT uenoh prognosticandpredictivevaluesoftumourbuddinginstageivcolorectalcancer